Luwy K Musey (Luwy Musey)

Publication Activity (10 Years)

Years Active: 2021-2021
Publications (10 Years): 6

Top Topics

Top Venues

Expert review of vaccines

Human vaccines & immunotherapeutics

Open forum infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Allan W Cripps, Temitope Folaranmi, Kelly D Johnson, Luwy K Musey, Michael S Niederman, Ulrike Kirsten Buchwald
Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert review of vaccines 20 (3) (2021)
Shahrul Mt-Isa, Lauren A Abderhalden, Luwy K Musey, Thomas Weiss
Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert review of vaccines (2021)
Michael S Niederman, Temitope Folaranmi, Ulrike Kirsten Buchwald, Luwy K Musey, Allan W Cripps, Kelly D Johnson
Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert review of vaccines 20 (3) (2021)
Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M Sterling, Katrina M Nolan, Gretchen M Tamms, Luwy K Musey, Ulrike Kirsten Buchwald
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Human vaccines & immunotherapeutics (2021)
Laura L Hammitt, Dean Quinn, Ewa Janczewska, Francisco J Pasquel, Richard Tytus, K Rajender Reddy, Katia Abarca, Ilsiyar M Khaertynova, Ron Dagan, Jennifer McCauley, Kyeongmi Cheon, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy K Musey, Ulrike K Buchwald
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open forum infectious diseases 9 (3) (2021)
Ulrike Kirsten Buchwald, Charles P Andrews, John Ervin, James T Peterson, Gretchen M Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea L Krick, Tina M Sterling, Meihua Wang, Jason C Martin, Jon E Stek, Melvin A Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy K Musey, null null
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Human vaccines & immunotherapeutics 17 (8) (2021)